What will be the next major milestone for CAN-2409 by end of 2025?
Initiation of Phase 4 trial • 25%
Regulatory approval in Europe • 25%
Launch of a new indication study • 25%
No major milestone announced • 25%
Official announcements from Candel Therapeutics
Candel Therapeutics' CAN-2409 Succeeds in Phase 3 Prostate Cancer Trial, Shares Soar
Dec 11, 2024, 12:48 PM
Candel Therapeutics announced that its experimental immunotherapy, CAN-2409, met the primary endpoint in a Phase 3 trial for prostate cancer, showing significantly improved disease-free survival. Following the announcement, the company's shares more than doubled in value in premarket trading. CAN-2409 is an oncolytic virus designed to stimulate the immune system to attack cancer cells. The trial's success marks a significant milestone for Candel Therapeutics, potentially paving the way for further development and regulatory approval of the treatment.
View original story
Regulatory approval application • 25%
Other milestone • 25%
Partnership with healthcare provider • 25%
Phase 2 trial initiation • 25%
Speed enhancement • 25%
Passenger comfort • 25%
Safety features • 25%
Energy efficiency • 25%
Establishment of a ground station • 25%
Launch of a second satellite • 25%
Other • 25%
Partnership with another space company • 25%
International collaboration • 25%
Full-scale production • 25%
Other • 25%
New advanced features • 25%
Miniaturization for smaller platforms • 25%
Increased power output • 25%
Other advancements • 25%
Integration with autonomous systems • 25%
No significant milestone • 25%
Phase 3 completion • 25%
Phase 2 completion • 25%
Phase 1 completion • 25%
Completion of Site Preparation • 25%
Start of Construction • 25%
First Major Funding Round • 25%
Partnership with New Stakeholders • 25%
Other • 25%
Coverage expansion announcement • 25%
New service launch • 25%
Technical upgrade • 25%
Rocket Launch • 25%
New Funding Round • 25%
Other • 25%
Partnership Announcement • 25%
Improved Error Correction • 25%
Increased Qubit Count • 25%
New Quantum Algorithm • 25%
Faster Computation Time • 25%
Asia coverage • 25%
North America coverage • 25%
Europe coverage • 25%
Global coverage • 25%
Enhanced Privacy Controls • 25%
Improved Image Analysis • 25%
Advanced Voice Interaction • 25%
Other • 25%
No • 50%
Yes • 50%
More than $5 billion • 25%
$1 billion to $5 billion • 25%
$500 million to $1 billion • 25%
Less than $500 million • 25%